Current share price for ARGX : 66.900 € 2.4 (3.72%)+
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It , was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
| BRU Code | ARGX |
| Industry/Sector | Biotechnology |
| Market Cap (€M) | n/a |
| ARGX Share Price | 66.900 € |
| Day High | 67.200 € |
| Day Low | 66.000 € |
| Last Close | 64.500 € |
| ARGX Share Price Movement | 2.40 € ( 3.72% ) |
ARGENX SE (ARGX) is held across 26 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ARGX moves, funds like VNGS, ESTX, ESGI, VMIN and HEUR that hold it can move with it.
For more concentrated exposure, ETFs such as VNGS (Vaughan Nelson Global SMID Fund (Managed Fund)) allocate about 1.4% to ARGX , while the average exposure across all 26 ETFs that hold it is around 0.4% .
Last updated: ETF data and holdings as at 12 September 2026
How does holding ARGENX SE (ARGX) shares directly compare to ETFs that include it?
|
ARGX Direct
|
VNGS
ASX |
ESTX
ASX |
ESGI
ASX |
VMIN
ASX |
HEUR
ASX |
|
|---|---|---|---|---|---|---|
| Holdings | 1 company | 78 holdings | 50 holdings | 247 holdings | 215 holdings | 234 holdings |
| ARGX Weight | 100% | 1.4% | 1.2% | 1.1% | 1% | 1% |
| Diversification | Single Stock | Broad | Broad | Broad | Broad | Broad |
| Annual Cost | Brokerage only | 1.12% p.a. | 0.35% p.a. | 0.55% p.a. | 0.28% p.a. | 0.56% p.a. |
| Approx. Yield | - | 1.72% | 7.33% | 2.75% | 12.31% | 4.32% |
| Star Ratings | - |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ARGX's direct yield. Annual cost uses each ETF's MER.
How a $10,000 investment in ARGENX SE (ARGX) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| ARGENX SE (ARGX) | Direct share | 66.900 € | 2.92% | +292 € | 10 292 € |
| Vaughan Nelson Global SMID Fund (Managed Fund) (VNGS) | Equity - Global Strategy | 3.730 € | -1.58% | -158 € | 9 842 € |
| Global X EURO STOXX 50 ETF (ESTX) | Equity - Global | 106.550 € | -1.07% | -107 € | 9 893 € |
| VanEck MSCI International Sustainable Equity ETF (ESGI) | Equity - Global | 37.050 € | -1.57% | -157 € | 9 843 € |
| Vanguard Global Minimum Volatility Active ETF (Managed Fund) (VMIN) | Equity - Global Strategy | 61.650 € | -1.27% | -127 € | 9 873 € |
| Betashares Europe ETF-Currency Hedged (HEUR) | Equity - Global | 18.170 € | -1.57% | -157 € | 9 843 € |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
26 ETFs hold ARGENX SE (ARGX).
| ETF | ARGX Weight | MER | Yield |
|---|---|---|---|
| Vaughan Nelson Global SMID Fund (Managed Fund) (VNGS) | 1.4% | 1.12% | 1.72% |
| Global X EURO STOXX 50 ETF (ESTX) | 1.2% | 0.35% | 7.33% |
| VanEck MSCI International Sustainable Equity ETF (ESGI) | 1.1% | 0.55% | 2.75% |
| Vanguard Global Minimum Volatility Active ETF (Managed Fund) (VMIN) | 1% | 0.28% | 12.31% |
| Betashares Europe ETF-Currency Hedged (HEUR) | 1% | 0.56% | 4.32% |
| Betashares Global Quality Leaders ETF (QLTY) | 0.9% | 0.29% | 3.46% |
| Betashares Global Healthcare ETF - Currency Hedged (DRUG) | 0.9% | 0.47% | 3.97% |
| Candriam Sustainable Global Equity Fund - Active ETF (GSUS) | 0.6% | 0% | 3.3% |
| iShares Edge MSCI World Minimum Volatility ETF (WVOL) | 0.5% | 0.25% | 2.13% |
| Global X S&P World ex Australia GARP ETF (GARP) | 0.4% | 0.3% | 6.1% |
| Operating Revenue Per Share | Price to Operating revenue | Price to free cash flow | Earnings Yield | PE Ratio | Dividend Yield | Forward Dividend Yield | Forward Earnings Yield |
|---|---|---|---|---|---|---|---|
| 14.85 € | 57.50 € | 71.90 € | 2.64% | 37.93 | n/a | n/a | 3.71 |
| Created Date | Changed Date | Event |
|---|---|---|
| 04 August 2026 | 04 August 2026 | Company Meeting |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.